VivoSeq
Other

S-Ketamine

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

S-ketamine is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Unknown status1 · 25%

Clinical Trials

Trial Activity

The Preemptive Analgetic Potency of Low Dose S-Ketamine
Completed·MMedical University of Graz·Phase 3·NCT01022840·60 enrolled
The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam
Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT01275547·22 enrolled
Racemic Ketamine Versus S-ketamine With Arterial Spin Labeling (ASL)-MRI in Healthy Volunteers
Completed·LLund University·N/A·NCT01506921·14 enrolled
The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)
Unknown status·—·N/A·NCT04399070·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)